ACQUISITIONS and MERGERS
1 min.Read

Quilvest Acquires Majority Interest in UrgentMED

Quilvest Capital Partners (“Quilvest”), a leading global private investment firm, is announced that it has made a substantial growth investment in UrgentMED, the premier independent network of urgent care clinics in Southern California. Quilvest is partnering with UrgentMED’s co-founders, Dr. Jacob Rastegar, Dr. Morris Kokhab, and Dr. Pejman Bolourian, who will each remain significant shareholders and will continue to lead the business going forward.  The financial terms of the transaction were not disclosed.

Founded in 2007 and headquartered in West Hollywood, California, UrgentMED operates 35 urgent care clinics in the Southern California region, including Los Angeles County, Orange County and Ventura County.

“We are thrilled to partner with Drs. Rastegar, Kokhab and Bolourian,” said Jay Takefman, Partner and Co-Head of Direct Private Equity at Quilvest. “UrgentMED has established itself as the leading independent urgent care network in Southern California and is ideally positioned to meet consumers’ and payors’ demands for convenient, affordable and high-quality care by deploying its broad healthcare offering across its clinic footprint. We look forward to joining UrgentMED on the next phase of its journey as the company continues its growth strategy,” he added.

Dr. Rastegar, Dr. Kokhab and Dr. Bolourian (co-founders and co-CEOs), stated: “We welcome the Quilvest team to the UrgentMED family. Quilvest is an ideal partner for us due to its deep understanding of multi-unit business models, healthcare sector expertise and vast network of resources to help us grow.  We are excited to have a supportive partner who shares our vision.”

Benjamin Sass, Principal at Quilvest, added: “UrgentMED is an exceptional business led by an exceptional team. We look forward to helping UrgentMED accelerate its expansion strategy, while continuing to leverage UrgentMED’s patient-centric model and culture of care.”

Quilvest was advised by Piper Sandler and Dechert LLP. UrgentMED was advised by FocalPoint Securities LLC and Sheppard, Mullin, Richter & Hampton.

SourceQuilvest Capital Partners

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

0
Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

0
Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

0
Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

0
The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

0
“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330